http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2261447-C1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74 |
| filingDate | 2004-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2005-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e99e1cde3a86cbb93df38815622006e5 |
| publicationDate | 2005-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2261447-C1 |
| titleOfInvention | Method for diagnosing obliterated forms of congenital suprarenal gland cortex hyperplasia |
| abstract | FIELD: medicine. n SUBSTANCE: method involves applying high effectiveness liquid chromatography for determining cortisol, cortisone 11-deoxycorticosterone, 11-deoxycortisone concentration in blood and free cortisol and free cortisone excretion with urine. Ratios of F/E and FF/FE are calculated, where F is the cortisol level in blood; E is the cortisone level in blood; FF is the free cortisol excretion with urine and FE is the free cortisone excretion with urine. The cortisol level in blood not exceeding norm and at least two of three signs: F/E ratio reduction by 25% and more, FF/FE ratio reduction by 25% and more, free cortisol excretion with urine being equal to 25% and more, obliterated forms of congenital suprarenal gland cortex hyperplasia is diagnosed. Corticosterone level in blood growing by 50% and higher, 21-hydroxylase defect is considered to be the case. 11-deoxycorticosterone and/or 11-deoxycortisone concentration in blood being et or greater than 50%, 11β-hydroxylase defect is considered to be the case. n EFFECT: high accuracy of early stage diagnosis. n 1 tbl |
| priorityDate | 2004-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 57.